Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy

Prostate

Volumn 28, Issue 4, 1996, Pages 227-231

  Van Der Kwast, T H ^a   Tetu B ^b   Fradet, Y ^b   Dupont, A ^c   Gomez, J ^c   Cusan, L ^c   Diamond, P ^c   Labrie, F ^c  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

androgen receptor; antiandrogen; endocrine combination therapy; human prostate; LHRH agonist

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; RECEPTOR DENSITY; SCORING SYSTEM;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; DRUG THERAPY, COMBINATION; EPITHELIAL CELLS; EPITHELIUM; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS;

EID: 0029996145     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199604)28:4<227::AID-PROS3>3.0.CO;2-A     Document Type: Article

References (23)

1. Ruizeveld de Winter JA, Trapman J, Brinkmann AO, Boersma WJA, Mulder E, Schroeder FH, Claassen E, van der Kwast TH: Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 161:329-332, 1990.
2. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH: Androgen receptor expression in human tissues: An immunohistochemical study. J Histochem Cytochem 39:927-936, 1991.
3. Sar M, Lubahn DB, French FS, Wilson EM: Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127:3180-3186, 1990.
4. Prins GS, Birch L, Greene GL: Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 129:3187-3199, 1991.
5. Bonkhoff H, Remberger K: Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch [A] 422:35-38, 1993.
6. Takeda H, Nakamoto T, Kokontis J, Chodak GW, Chang C: Autoregulation of androgen receptor expression in rodent prostate: Immunohistochemical and in situ hybridization analysis. Biochem Biophys Res Commun 177:488-496, 1991.
7. Shan L-X, Rodriguez MC, Jänne OA: Regulation of androgen receptor protein and mRNA concentrations by androgens in rat ventral rat prostate and seminal vesicles and in human hepatoma cells. Mol Endocrinol 4:1636-1646, 1990.
8. Prins GS: Differential regulation of androgen receptors in the separate rat prostate lobes: Androgen independent expression in the lateral lobe. J Steroid Biochem 33:319-326, 1989.
9. Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Constantini A, Serio M, Martini L, Motta M: Three-months treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: Effects on tissue androgen concentration, 5α-reductase activity and androgen receptor content. J Clin Endocrinol Metab 68:461-468, 1989.
10. Labrie F: Intracrinology. Mol Cell Endocrinol 78:113-118, 1991.
11. Labrie F, Belanger A, Dupont A, Van L-T, Simard J, Labrie C: Science behind total androgen blockade: From gene to combination therapy. Clin Invest Med 16:474-492, 1993.
12. Têtu B, Srigley JR, Boivin J-C, Dupont A, Monfette G, Pinault S, Labrie F: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. Am J Surg Pathol 15:111-120, 1991.
13. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Emon J, Candas B: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial. Clin Invest Med 16:499-509, 1993.
14. Jenster G, van der Korput JAGM, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO: Domains of the human androgen receptor involved in steroid-binding, transcriptional activation and subcellular localization. Mol Endocrinol 5:1396-1404, 1991.
15. Veldscholte J, Berrevoets CA, Zegers ND, van der Kwast TH, Grootegoed JA, Mulder E: Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: Use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31:7422-7430, 1992.
16. Peters CA, Walsh PC: The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317:599-604, 1987.
17. Vickery BH, McRae GI, Briones W, Worden A, Seidenberg R, Schanbacher BD, Falvo R: Effects of an LHRH agonist analog upon sexual function in male dogs. Suppression, reversibility, and effect of testosterone replacement. J Androl 5:28-42, 1984.
18. Merk FB, Warhol MJ, Kwan PW-L, Leav I, Alroy J, Ofner P, Pinkus G: Multiple phenotypes of prostatic glandular cells in castrated dogs after individual or combined treatment with androgen and estrogen. Lab Invest 54:442-456, 1986.
19. Merk FB, Ofner P, Kwan PW-L, Leav I, Vena RL: Ultrastructural and biochemical expression of divergent differentiation in prostates of castrated dogs treated with estrogen and androgen. Lab Invest 47:437-450, 1982.
20. Bosch RJLH, Griffith DJ, Blom JHM, Schroeder FH: Treatment of benign prostatic hyperplasia by androgen deprivation: Effects on prostate size and urodynamic parameters. J Urol 141:68-72, 1989.
21. Krongrad A, Wilson CM, Wilson JD, Allman DR, McPhaul MJ: Androgen increases androgen receptor protein, while decreasing mRNA in LNCaP cells. Mol Cell Endocrinol 76:79-88, 1991.
22. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CCJ, Mulder E, Boersma W, Trapman J: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193, 1991.
23. Ruizeveld de Winter JA, Janssen PJA, Sleddens HMFB, Verleun-Mooijman MCT, Trapman J, Brinkmann AO, Santerse AB, Schröder FH, van der Kwast TH: Androgen receptor status in localized and locally progressive, hormone refractory human prostate cancer. Am J Pathol 144:735-746, 1994.